BioSight
Companies
Humacyte, Inc. logo

HUMA

NASDAQDURHAM, NC
Humacyte, Inc.

Humacyte develops tissue-engineered blood vessels (called ATEVs) for vascular access and other clinical applications. The company has one product, Symvess, which is in the regulatory approval process with the FDA and other authorities. Humacyte is at an early commercialization stage, focusing on manufacturing scale-up and regulatory clearance to bring Symvess to market.

Price history not yet available for HUMA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar